We are officially enrolling patients in the NEWTON2 trial in Tallahassee!

I’m proud to announce that Tallahassee Neurological Clinic (TNC) is participating the NEWTON2 trial, and we are currently enrolling patients.  NEWTON2 is a phase 3 randomized trial evaluating intraventricular nimodipine (EG-1962) versus standard of care oral nimodipine in patients with subarachnoid hemorrhage due to ruptured brain aneurysms.  This makes Tallahassee the only center in the region that provides full service cerebrovascular care and cutting edge stroke and brain aneurysm research.

Noncontrast CT scan of the head showing classic appearance of subarachnoid hemorrhage.

Participating in well designed clinical trials, such as NEWTON2, helps ensure that the care we provide in the future will be better than the care we provide today. I’m very proud that we are participating in this trial, as it helps advance our field within neurosurgery, and hopefully will improve outcomes for patients with subarachnoid hemorrhage.

TNC is the only neurosurgical group in the region with three endovascular neurosurgeons, who provide comprehensive care for ischemic stroke, hemorrhagic stroke, brain aneurysms, and carotid disease.  We have an active clinical research division and have participated in numerous device and drug trials for neurosurgical patients.

TNC Endovascular Neurosurgeons. Left to right: Dr. Beaty, Dr. Oliver, and Dr. Lawson.

To learn more about the novel compound, EG-1962, please visit edge therapeutics:  http://www.edgetherapeutics.com/pipeline/#eg-1962

To learn more about NEWTON2, visit clinicaltrials.gov

Tallahassee selected as a site for NEWTON2 trial

Tallahassee Neurological Clinic and Tallahassee Memorial Hospital have been selected as a site for the NEWTON2 trial, with Dr. Lawson as the local site primary investigator.  This phase 3 trial is designed to study the efficacy of a novel substance compared to oral nimodipine for prevention of vasospasm in subarachnoid hemorrhage.  This makes TNC and the TMH Comprehensive Stroke Center the only center in the region participating in phase 3 research in hemorrhagic stroke & subarachnoid hemorrhage treatments.

Institutional Review Board approval has not yet been granted, but we hope to finalize this in the next few months.  The study is funded by Edge Therapeutics.

To learn more about the trial, click here.

TMH is one of 28 sites in the U.S. participating in the Barrel Trial for brain aneurysm treatment.

Drs. Lawson and Oliver at Tallahassee Neurological Clinic (TNC) are enrolling patients in the Barrel Trial, a study to evaluate the safety and efficacy of a new intracranial stent. TNC/TMH is one of only 28 centers in the United States selected to participate in the trial.

Read the TMH press release here.

Read the article in the Tallahassee Democrat here.